Skip to content

5-MeO-DMT: all studies

Page 57 of 110: studies 561 to 570 of 1,097, newest first. Back to the 5-MeO-DMT overview

Research

Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring.

ACS Medicinal Chemistry Letters February 13, 2025 Robert B. Kargbo

Integrating advanced pharmaceutical innovations and artificial intelligence (AI) offers transformative potential for psychiatric care. This Patent Highlight reviews novel therapeutic strategies, including the synergistic use of monoamine antidepressants and short-duration psychedelics, alongside AI-driven behavioral efficacy tracking. The combination of selective serotonin reuptake inhibitors...

Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression

Nature Communications February 12, 2025 Farid Aboharb, Pasha A. Davoudian, Ling-Xiao Shao et al. 19 citations

Psilocybin, ketamine, and MDMA are psychoactive compounds that exert behavioral effects with distinguishable but also overlapping features. The growing interest in using these compounds as therapeutics necessitates preclinical assays that can accurately screen psychedelics and related analogs. We posit that a promising approach may be to measure drug action on markers of neural plasticity in...

Can psychedelic use benefit meditation practice? Examining individual, psychedelic, and meditation-related factors.

PLoS One February 12, 2025 Zishan Jiwani, Simon B. Goldberg, Jack Stroud et al. 3 citations

INTRODUCTION: Meditation practice and psychedelic use have attracted increasing attention in the public sphere and scientific research. Both methods induce non-ordinary states of consciousness that may have significant therapeutic benefits. Thus, there is growing scientific interest in potential synergies between psychedelic use and meditation practice with some research suggesting that...

Plant-derived compounds and neurodegenerative diseases: Different mechanisms of action with therapeutic potential.

Neuroscience February 6, 2025 Carolina Echeverry, Mariana Pazos, Maximiliano Torres-Pérez et al. 9 citations

Neurodegenerative diseases are a group of disorders characterized by progressive degeneration of discrete groups of neurons causing severe disability. The main risk factor is age, hence their incidence is rapidly increasing worldwide due to the rise in life expectancy. Although the causes of the disease are not identified in about 90% of the cases, in the last decades there has been great...

Application of microarray patches for the transdermal administration of psychedelic drugs in micro-doses.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V February 1, 2025 Octavio E Fandiño, Aaron R J Hutton, Chunyang Zhang et al. 4 citations

Throughout history, psychedelic compounds have been used for religious, spiritual and recreational purposes. A plethora of studies have reported the use of psychedelic compounds in the treatment of various conditions, such as alcoholism, addictions, depressive state to borderline schizophrenia, personality disorder, among other mental disorders. Psychedelic microdosing, a common technique in...

Yopo (Anadenanthera peregrina (L.) Speg. Fabaceae)

January 23, 2025 Noureddine Chaachouay, Allal Douira, Lahcen Zidane

Anadenanthera peregrina (L.) Speg., sometimes called Cohoba or Yopo, is a plant species that falls under the scientific classification of the Fabaceae family under the Fabales order in the plant kingdom. It belongs to the Anadenanthera genus. This woody plant may grow to a height of 27 meters, forming various shapes, from small shrubs to massive trees. Anadenanthera peregrina (L.) Speg....

DOI: 10.1201/9781003460336-19 (opens in new tab) Fabaceae Botany Bioactive natural compounds Rabbits

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research

Repository for Publications and Research Data 2025 Kurt Stocker, Matthias Hartmann, Yasmin Schmid et al.

Background: The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-ASC offers superior model fit, the...

DOI: 10.3929/ethz-c-000791180 (opens in new tab) Anxiety Revalidation Confirmatory factor analysis Rating scale +20

The effects of psychedelics on neuroplasticity: A review of current research and the possibility of therapeutic application in psychiatry

Engrami 2025 Mile Jevtić 1 citation

Psychedelics are psychoactive substances that cause changes in perception, state of consciousness, mood and numerous cognitive processes. The best known are lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), psilocybin and mescaline. The main mechanism of action of psychedelics is agonism towards serotonin 5-HT2A receptors. In the middle of the 20th century, interest in the use of...

Expressive resource in a clinical psychedelic study: Art as an integration tool.

Progress in Brain Research 2025 Handersson Barros, Marcelo Falchi-Carvalho, Lucas O. Maia et al. 2 citations

Psychedelic experiences, especially those induced by substances such as N,N-Dimethyltryptamine (DMT), are often characterized by high subjective intensity, complex visual content, and notable ineffability-that is, the difficulty of being fully expressed in words. This expressive limitation poses a significant challenge to the integration of the experience, which is essential for the therapeutic...

DOI: 10.1016/bs.pbr.2025.07.004 (opens in new tab) Full text (opens in new tab) Clinical trials Expressive resource Mandala N,N-Dimethyltryptamine DMT +2

Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community

Figshare 2025 Daniel J. Kruger, Gina Mersereau, Ashley Sullivan et al. preprint

Abstract Background The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeutic applications of psychedelics may result in a record number of people who use psychedelics for the first-time. This study aimed to develop a harm-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated...